Pulmonx Corp
NASDAQ:LUNG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (19.2), the stock would be worth $-58.41 (4 492% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.4 | $1.33 |
0%
|
| Industry Average | 19.2 | $-58.41 |
-4 492%
|
| Country Average | 19.6 | $-59.54 |
-4 577%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Pulmonx Corp
NASDAQ:LUNG
|
55.4m USD | -0.4 | -1 | |
| US |
M
|
Medline Inc
NASDAQ:MDLN
|
62.4B USD | 0 | 0 | |
| JP |
|
Hoya Corp
TSE:7741
|
9.7T JPY | 33.7 | 38.7 | |
| CH |
|
Alcon AG
SIX:ALC
|
30.1B CHF | 28.2 | 37.7 | |
| DK |
|
Coloplast A/S
CSE:COLO B
|
96.5B DKK | 15.2 | 24 | |
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.9B USD | 20.4 | 34 | |
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
4.5B GBP | 18.3 | 33.6 | |
| CA |
|
Bausch + Lomb Corp
NYSE:BLCO
|
5.7B USD | 54.9 | -15.7 | |
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
8.3T KRW | -79.5 | -37.5 | |
| JP |
A
|
Asahi Intecc Co Ltd
TSE:7747
|
868.9B JPY | 31.5 | 49.1 | |
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.3B USD | 17.8 | 22.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
Pulmonx Corp
Glance View
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
